BiotechTV

CEO Morten Graugaard discusses the limitations of previous generations of macrocycles and describes what he believes the power is behind the Orbis platform.

European Biotechnology

In the evolving landscape of drug discovery and new design, scientists and pharmaceutical innovators ­continually strive to develop therapies that are both highly ­selective and clinically effective, while addressing targets ­previously deemed “undruggable”. In recent years, macrocycles – a class of large, ring-shaped molecules – have emerged as a compelling solution at the crossroads between ­traditional small molecules and large biologics, offering a blend of high specificity, rich chemical diversity and promising pharma­cological profiles.

Pharmaceutical Executive

In a conversation with Pharmaceutical Executive, Morten Graugaard discussed FDA’s approval of Icotyde as an early validation point for oral biologics, describing it as a meaningful step toward translating the efficacy and target engagement of biologics into more accessible oral formats.

Drug Target Review

New macrocycle technologies are turning a once difficult drug class into a scalable engine for developing potent oral therapies.

The Bio Report

Orbis Medicines is developing orally available synthetic macrocycles called ⁿCycles that can target diseases typically requiring biologic therapies, offering a novel alternative through its platform technology.

Pharma Boardroom

As pharmaceutical companies race to replace injectable therapies with more accessible oral biologics, Orbis Medicines is leading the charge with its next-generation macrocycle platform and AI-powered discovery engine.

Base to Base Biotech by Jim Cornall

Orbis Medicines is revolutionizing macrocycle drug development by combining AI, big data, and high-throughput synthesis to make this complex class of molecules reliably designable and orally available for the first time.

Endpoints News

European biotech Orbis Medicines has raised €90 million in Series A funding to advance its AI-driven platform for designing oral macrocycle drugs targeting diseases traditionally treated with injectable biologics.

Biopharma Dive

Orbis Medicines has raised $93 million to develop oral macrocyclic peptides that combine the power of biologics with the convenience of pills, aiming to replace injectable drugs for hard-to-treat disease targets.